KILITCHPharmaceuticals
Kilitch Drugs India Ltd — Profit & Loss Statement
₹124.45
-9.06%
Kilitch Drugs India Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.25 Cr | 0.32 Cr | — |
| Tax Rate For Calcs | 0.28 | 0.30 | 0.31 | 0.35 | — |
| Normalized EBITDA | 42.63 Cr | 28.63 Cr | 19.67 Cr | 12.38 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.82 Cr | 0.90 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.82 Cr | 0.90 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 26.70 Cr | 14.60 Cr | 10.45 Cr | 7.37 Cr | — |
| Reconciled Depreciation | 3.11 Cr | 3.35 Cr | 3.55 Cr | 2.47 Cr | — |
| Reconciled Cost Of Revenue | 104.58 Cr | 78.96 Cr | 77.13 Cr | 68.25 Cr | — |
| EBITDA | 42.63 Cr | 28.63 Cr | 20.48 Cr | 13.28 Cr | — |
| EBIT | 39.52 Cr | 25.28 Cr | 16.93 Cr | 10.81 Cr | — |
| Net Interest Income | -5.04 Cr | -5.93 Cr | -4.78 Cr | -1.11 Cr | — |
| Interest Expense | 5.04 Cr | 5.93 Cr | 4.92 Cr | 1.20 Cr | — |
| Normalized Income | 26.70 Cr | 14.60 Cr | 9.88 Cr | 6.78 Cr | — |
| Net Income From Continuing And Discontinued Operation | 26.70 Cr | 14.60 Cr | 10.45 Cr | 7.37 Cr | — |
| Total Expenses | 169.96 Cr | 133.57 Cr | 124.51 Cr | 103.20 Cr | — |
| Diluted Average Shares | 1.61 Cr | 1.59 Cr | 1.56 Cr | 1.56 Cr | — |
| Basic Average Shares | 1.61 Cr | 1.59 Cr | 1.56 Cr | 1.56 Cr | — |
| Diluted EPS | 16.60 | 9.17 | 6.71 | 4.73 | — |
| Basic EPS | 16.60 | 9.17 | 6.71 | 4.73 | — |
| Diluted NI Availto Com Stockholders | 26.70 Cr | 14.60 Cr | 10.45 Cr | 7.37 Cr | — |
| Net Income Common Stockholders | 26.70 Cr | 14.60 Cr | 10.45 Cr | 7.37 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 26.70 Cr | 14.60 Cr | 10.45 Cr | 7.37 Cr | — |
| Minority Interests | 1.76 Cr | 1.03 Cr | 2.17 Cr | 1.15 Cr | — |
| Net Income Including Noncontrolling Interests | 24.94 Cr | 13.58 Cr | 8.28 Cr | 6.21 Cr | — |
| Net Income Continuous Operations | 24.94 Cr | 13.58 Cr | 8.28 Cr | 6.21 Cr | — |
| Tax Provision | 9.53 Cr | 5.78 Cr | 3.73 Cr | 3.40 Cr | — |
| Pretax Income | 34.47 Cr | 19.35 Cr | 12.01 Cr | 9.61 Cr | — |
| Other Non Operating Income Expenses | 11.16 Cr | 4.48 Cr | 0.06 Cr | 0.26 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -0.17 Cr | -0.46 Cr | — |
| Net Non Operating Interest Income Expense | -5.04 Cr | -5.93 Cr | -4.78 Cr | -1.11 Cr | — |
| Interest Expense Non Operating | 5.04 Cr | 5.93 Cr | 4.92 Cr | 1.20 Cr | — |
| Operating Income | 28.35 Cr | 20.80 Cr | 14.35 Cr | 9.76 Cr | — |
| Operating Expense | 65.38 Cr | 54.61 Cr | 47.37 Cr | 34.94 Cr | — |
| Other Operating Expenses | 50.95 Cr | 41.24 Cr | 27.41 Cr | 21.38 Cr | — |
| Depreciation And Amortization In Income Statement | 3.11 Cr | 3.35 Cr | 3.55 Cr | 2.47 Cr | — |
| Depreciation Income Statement | 3.11 Cr | 3.35 Cr | 3.55 Cr | 2.47 Cr | — |
| Gross Profit | 93.74 Cr | 75.41 Cr | 61.72 Cr | 44.71 Cr | — |
| Cost Of Revenue | 104.58 Cr | 78.96 Cr | 77.13 Cr | 68.25 Cr | — |
| Total Revenue | 198.32 Cr | 154.37 Cr | 138.86 Cr | 112.96 Cr | — |
| Operating Revenue | 198.32 Cr | 154.37 Cr | 138.86 Cr | 112.96 Cr | — |
| Interest Income | — | 0.41 Cr | 0.30 Cr | 0.22 Cr | 0.17 Cr |
| Rent Expense Supplemental | — | 1.39 Cr | 0.38 Cr | 0.49 Cr | 0.32 Cr |
| Write Off | — | 0.02 Cr | 0.17 Cr | 0.46 Cr | 0.34 Cr |
| Total Other Finance Cost | — | 0.11 Cr | 0.16 Cr | 0.13 Cr | 0.12 Cr |
| Interest Income Non Operating | — | 0.41 Cr | 0.30 Cr | 0.22 Cr | 0.17 Cr |
| Selling General And Administration | — | 4.87 Cr | 2.65 Cr | 2.68 Cr | 2.83 Cr |
| Selling And Marketing Expense | — | 1.11 Cr | 0.66 Cr | 0.73 Cr | 0.68 Cr |
| General And Administrative Expense | — | 3.76 Cr | 1.99 Cr | 1.95 Cr | 2.15 Cr |
| Rent And Landing Fees | — | 1.39 Cr | 0.38 Cr | 0.49 Cr | 0.32 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Kilitch Drugs India Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.